Clinical trial
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or…
NCT00489359 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00489359 |
|---|---|
| Title | Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer |
| Official title | A Phase 1 and 2 Clinical Trial of ALIMTA® (Pemetrexed) in Combination With Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed - Phase 1, Carboplatin - Phase 1, Pemetrexed - Phase 2, Carboplatin - Phase 2 |
| Enrollment | 86 |
| Start date | Jul 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jun 21, 2007 |
| Last update posted | Jun 16, 2011 |
| Countries | Argentina, Canada, Germany, Poland, Sweden |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: